Please login to the form below
Quad
This page shows the latest Quad news and features for those working in and with pharma, biotech and healthcare.
ViiV takes two-drug cocktail for first-line HIV into phase III
HIV therapies that combine multiple drugs into one tablet such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and Gilead's Quad product (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) are expected to be
Latest news
-
Aurobindo joins Patent Pool
Quad (a combination of the three drugs and tenofovir).
-
Gilead agrees HIV patent pool deal
as a combination pill to be called Quad.
-
Gilead's HIV drug meets phase III endpoint
Gilead is studying the use of elvitegravir as part of a separate investigational fixed-dose, single-tablet "Quad" regimen. ... Quad pill," said Dr Norbert Bischofberger, executive vice president, R&D and chief scientific officer, Gilead Sciences. .
-
A competitive edge
An exciting new four-in-one fixed-dose tablet, known as "Quad", has been developed by Gilead Sciences. ... CROI. These results demonstrated that the Quad regimen exhibited antiretroviral activity comparable to that of Atripla.
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Medical Editor
-
Competitive
-
Healthcare Account Director
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- AstraZeneca reduces initial COVID-19 vaccine deliveries to the EU
- Pfizer/BioNTech reach vaccine supply agreement with COVAX
- Trial combining British and Russian COVID-19 vaccines could begin in February
- AstraZeneca reduces initial COVID-19 vaccine deliveries to the EU
- AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly
- Patient recruitment and retention 2021 state of play
- Live Webinar: Women in Leadership: Barriers & Opportunities in the Life Science Industry
- The UK has approved the first vaccine for COVID-19. What now?
- Clinical trials and the diversity principle
- Publicis Health UK Launches Unique Agency Offering for Clients Under Langland
- Sanofi will provide manufacturing support for Pfizer/BioNTech’s COVID-19 vaccine
PMHub
11 London
11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...
Latest intelligence
- Patient recruitment and retention 2021 state of play
- At COUCH Health, we’ve recently done some social listening to look into the discussions around ‘patient recruitment’ and ‘patient retention’, to see if these conversations have been impacted by the...
- The UK has approved the first vaccine for COVID-19. What now?
- The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
- Clinical trials and the diversity principle
- If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....
Quick links
Infographics
